Evidence map›Paper›PMID 17699731›Full record

ArticleMolecular cancer therapeutics2007

Development of a fluorescence-based assay to screen antiviral drugs against Kaposi's sarcoma associated herpesvirus.

Tamara K Nun, David J Kroll, Nicholas H Oberlies, Djaja D Soejarto, Ryan J Case, Pius Piskaut, Teatulohi Matainaho, Chelsey Hilscher, Ling Wang, Dirk P Dittmer and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer therapeutics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Update on HHV-8-Associated Malignancies.Current infectious disease reports · 2010
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Tamara K NunDepartment of Microbiology and Immunology, Lineberger Cancer Center, University of North Carolina at Chapel Hill, North Carolina, NC 27599, USA.
David J Kroll
Nicholas H Oberlies
Djaja D Soejarto
Ryan J Case
Pius Piskaut
Teatulohi Matainaho
Chelsey Hilscher
Ling Wang
Dirk P Dittmer
Shou-Jian Gao
Blossom Damania
University of North Carolina at Chapel Hill · USUniversity of Illinois Chicago · USUniversity of Papua New Guinea · PGResearch Triangle Park Foundation · USRTI International · USThe University of Texas Health Science Center at San Antonio · US

Funding

Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
ART Modulation of Viral Pathogenesis in Oral EpitheliaR01DE018304 · NIDCR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DITTMER, DIRK P · 2007 to 2025
$6.9M
Role of KSHV Viral Proteins in Signaling and PathogenesisR01CA096500 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAMANIA, BLOSSOM A · 2002 to 2022
$6.0M
Targeted Therapies for HIV-Associated Kaposi Sarcoma and LymphomaR01CA163217 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BLOSSOM A DAMANIA, Dirk P Dittmer · 2011 to 2026
$5.5M
CANCER CELL BIOLOGY TRAINING PROGRAMT32CA071341 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHANNING J. DER, Yuliya Pylayeva-Gupta · 1996 to 2026
$5.0M
Molecular Biology of Viral Diseases Predoctoral Training GrantT32AI007419 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Mark T Heise, CARY A MOODY · 1993 to 2026
$4.7M
PLANT SELECTION, COLLECTION AND PROJECT DATA MANAGEMENTU19CA052956 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI KINGHORN, ALAN DOUGLAS · 1995 to 2004
$4.4M
Innate Immunity and KSHVR01DE018281 · NIDCR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAMANIA, BLOSSOM A · 2007 to 2016
$3.5M
Regulation of the KSHV Latent PromoterR01CA109232 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DITTMER, DIRK P · 2004 to 2014
$2.5M
Viral Infection and Primary Pulmonary HypertensionR01HL083469 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAMANIA, BLOSSOM A · 2005 to 2009
$1.8M
NCI NIH HHS 2T32CA071341NCI NIH HHS CA096500NCI NIH HHS CA109232NCI NIH HHS R01 CA096500NCI NIH HHS R01 CA109232NCI NIH HHS R01 CA163217NCI NIH HHS T32 CA071341NCI NIH HHS U19 CA052956NCI NIH HHS U19-CA52956NHLBI NIH HHS HL083469NHLBI NIH HHS R01 HL083469NIAID NIH HHS 2P30AI050410NIAID NIH HHS 5T32AI007419NIAID NIH HHS P30 AI050410NIAID NIH HHS T32 AI007419NIDCR NIH HHS DE018281NIDCR NIH HHS DE018304NIDCR NIH HHS R01 DE018281NIDCR NIH HHS R01 DE018304
6 · The paper itself

Abstract

Tumors associated with Kaposi's sarcoma-associated herpesvirus infection include Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Virtually all of the tumor cells in these cancers are latently infected and dependent on the virus for survival. Latent viral proteins maintain the viral genome and are required for tumorigenesis. Current prevention and treatment strategies are limited because they fail to specifically target the latent form of the virus, which can persist for the lifetime of the host. Thus, targeting latent viral proteins may prove to be an important therapeutic modality for existing tumors as well as in tumor prevention by reducing latent virus load. Here, we describe a novel fluorescence-based screening assay to monitor the maintenance of the Kaposi's sarcoma-associated herpesvirus genome in B lymphocyte cell lines and to identify compounds that induce its loss, resulting in tumor cell death.

Indexed as

Antigens, ViralAntiviral AgentsBiological AssayCell DeathDrug Evaluation, PreclinicalFluorescenceFluorescent Antibody TechniqueHerpesvirus 8, HumanHumansNuclear ProteinsPlant ExtractsReproducibility of ResultsReverse Transcriptase Polymerase Chain ReactionAntigens, ViralAntiviral Agentslatency-associated nuclear antigenNuclear ProteinsPlant Extracts

Identifiers

PMID17699731
PMCPMC3600170
OpenAlexW2161830390

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.